University of Maryland Medical Center Partners with CDEX to Implement Medication Validation Solution
CDEX’s ValiMed System Chosen by UMMS to Verify Compounded Medications and Doses, Validate Narcotic Returns, and Identify Counterfeit Pharmaceuticals
Rockville, MD and Baltimore, MD– November 29, 2005 –The University of Maryland Medical Center has selected the CDEX (OTCBB: CEXI) ValiMed system to perform end product testing of compounded intravenous medications in its pharmacy departments, and validation of returned narcotics in its operating room suites and nursing units. The CDEX ValiMed medication verification system was developed to give clinicians a quick, cost effective, and simple tool to further ensure medication safety by verifying medications are correctly compounded. The University of Maryland Medical Center (UMMC) is part of a private, not-for-profit organization that includes six hospitals and has more than 11,000 employees. The system provides a full range of primary and specialty care to people throughout Maryland and the Mid-Atlantic region. ValiMed will be installed at the University of Maryland Medical Center, a 655-bed teaching hospital.
In a process that takes only seconds, ValiMed uses patent pending technology to validate compounded doses of high-risk medications prior to dispensing. The solution creates an added level of safety in the medication dispensing process, and is also used to validate narcotic returns as well as identify counterfeit medications.
“We are focused on patient safety at UMMC, and the CDEX ValiMed product offers us an additional opportunity to validate the end products being dispensed from the pharmacy and to validate returned narcotics, ” said Marc Summerfield, Director of Pharmacy at UMMC. “With ValiMed, we will have an added level of safety on certain products that we dispense every day, and added cost-effective audit capabilities for our controlled substances compliance initiatives.”
“As the list of nationally-recognized healthcare providers using the ValiMed solution continues to grow, CDEX is particularly pleased that the University of Maryland Medical Center, a world-class hospital located in the same region where CDEX is headquartered, has selected this innovative, proven system for end-product medication testing and return narcotic validation,” said Malcolm Philips, CEO and Chairman of the Board for CDEX.”
The CDEX ValiMed solution uses light energy and a library of unique spectral fingerprints to validate drugs in solution. The device validates that the correct drugs in the correct amounts have been added to the dose during the compounding process.
About The University of Maryland Medical Center (UMMC)
For more information, visit www.umm.edu.
About CDEX, Inc.
CDEX Inc. is a technology development company with a current focus on developing and marketing products using chemical detection and validation technologies. At present, CDEX is devoting its resources to two distinct areas: (i) identification of substances of concern (e.g., explosives and illegal drugs for homeland security); and (ii) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of prescription medication and detection of counterfeit or sub-par products for brand protection). ValiMed is one line of CDEX products for the healthcare market. CDEX is headquartered in Rockville, Maryland with its research and development laboratory in Tucson, Arizona. For more information, visit www.cdex-inc.com and www.valimed.com or contact Jim Griffin or Jerry Blair at 301-881-0080 (cdexmanagement@cdex-inc.com).
